CLINICAL TRIAL SUMMARY

MDACC Study No:2004-0703 (clinicaltrials.gov NCT No: NCT00525915)
Title:AN OXALIPLATIN-BASED PHASE II RANDOMIZED STUDY OF INDUCTION CHEMOTHERAPY FOLLOWED BY PREOPERATIVE CHEMORADIOTHERAPY OR PREOPERATIVE CHEMORADIOTHERAPY IN PATIENTS WITH RESECTABLE ESOPHAGEAL OR GASTROESOPHAGEAL CARCINOMA
Principal Investigator:Jaffer Ajani
Treatment Agent:5-Fluorouracil; Oxaliplatin
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if a combination of the
investigational drug oxaliplatin with 5-FU (given at the same time as radiation
therapy) is as effective as a combination of these two drugs given before and
during radiation therapy in the treatment of esophageal or gastroesophageal
cancers. The safety of these combinations of therapy will also be compared.

Hide details for General InformationGeneral Information

Disease Group:Esophageal; Gastrointestinal
Phase of Study:Phase II
Treatment Agents:5-Fluorouracil
Oxaliplatin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None
Supported By:N/A
Return Visit:Twice a month
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jaffer Ajani
Dept:Gastrointestinal Medical Oncology
For Clinical Trial Enrollment:713-792-2828
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults